Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.
about
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trialsReview of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Aspirin for primary prevention of cardiovascular diseaseNew insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolismComparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-AnalysisA systematic review of aspirin in primary prevention: is it time for a new approach?Esomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsResults of observational studies: analysis of findings from the Nurses' Health StudyUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Coagulation and morbidity in treated HIV infection.Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.Oral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in elderly people in Poland.Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012.The role of aspirin in the prevention of cardiovascular disease.Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosisAspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis.Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancerIndividualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy womenDrugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.Association between use of specialty dietary supplements and C-reactive protein concentrations.Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes RegisterA randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudyEffect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in menLong-term prognosis in patients continuing taking antithrombotics after peptic ulcer bleeding.The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease.Acetylsalicylic acid/esomeprazole fixed-dose combination.Aspirin for primary prevention of cardiovascular events in the elderly: current status and future directions.Updates in antiplatelet agents used in cardiovascular diseases.Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review.Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population.Aspirin and incident depressive symptoms: A longitudinal cohort study over 8 years.Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and Meta-analysis.Antiplatelet treatment in the primary prophylaxis of cardiovascular disease in patients with arterial hypertension.Aspirin for Prevention of Cardiovascular Disease.Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?Aspirin for primary prevention: a challenging decision.Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.Evaluation of peritoneal endometriosis treatment using intralesional acetylsalicylic acid injection in rabbits.
P2860
Q21132402-BC85DC8B-9D5E-450A-BDD3-C80F327B4C1BQ22241777-43FA2EA0-FEBE-40F2-9227-A0243F7AFC32Q26774150-C8CB1BE3-8071-4F6D-B17C-7A7F9D6B953BQ26786574-85BCD05F-4684-416C-9F38-AC08D10A2548Q26798134-3B1C9541-70E3-4AC2-90AA-C535AC2C660CQ26864015-318D2710-C7DC-43DA-A57C-92602A62A212Q26995752-0B7ABABF-48AF-453B-9C9A-7DA6854D6900Q27006022-803413D6-264C-49A0-A035-6E7709049509Q27687851-D9101A4D-3FBD-48B1-9519-2F5EE8AA83ABQ33614424-5F784301-F30A-4E62-A1E6-7CBAD58CD5CCQ34433987-CEF28965-6A76-4D72-AA89-EFF0614166F5Q34462760-BAF9E881-E840-4FF7-B636-EA3D5E3FE3F8Q35026319-B236699B-BC02-49CE-AE67-5E2FB96E2C56Q35049359-427B9679-21D3-4450-94E2-63EBBA9D60B0Q35546421-C62082AC-A3F9-46AE-A4E1-2BFB6D4332C1Q35685250-10BC28FE-7066-4535-A1FD-60FCC7F0E2EFQ35794066-2DA2F07C-64ED-4404-90BF-147AEBC031CCQ35953560-50E483FB-63DF-4772-8E43-59559CB85BCAQ36082805-1858D830-FDF7-4437-B7F2-3260C0D86406Q36606633-4C988FC1-E37E-4178-813D-1FAA668BFFABQ36809851-67E6BE93-6D85-40BE-B162-9BBBCCE42146Q36932652-9EACA58E-7F05-48E5-A8C4-20C5E6F60DF5Q37231429-63A2D294-11C6-452A-AF00-E3B5931B2E7BQ37625235-98A40FC1-BF3C-431E-826A-8EB56AC18521Q37955226-50F7FAA5-8CAD-4AAF-856C-B3FCD0B88DA8Q37988928-F04B5456-01C0-4820-9D40-BC5DCB7CE471Q37998509-37B4014E-B37A-4D46-BA11-C28C9CDEAE2CQ38161394-F573CDCA-AD38-48CA-8440-3134F4E84AB2Q38211737-DA5E2E8B-7E81-4799-8CC5-734A6A406C74Q38271121-96D4CEB0-4E84-42AC-BE89-885504798E6DQ38637748-8D536CD8-AE9E-4A41-8F32-B0DA25B46859Q38829409-C4E0CC46-B7C3-41ED-BEB2-AAEA16944A34Q41076435-DDE943AF-312D-4270-8159-FBF6273481C6Q41511350-B30E04E1-8573-4EFA-992C-70A25490030AQ42097290-5B1151AB-8A10-4AF8-93E3-91F660DED7BDQ43123151-19B4CBE8-D905-4BD0-AE43-FA222E8811B3Q48338773-7E556255-CABC-493C-9F46-B8A563B7D9BFQ50899458-D850FC88-8418-4C27-BFF8-4C72328A8608
P2860
Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Aspirin for the prevention of ...... analysis of randomized trials.
@ast
Aspirin for the prevention of ...... analysis of randomized trials.
@en
Aspirin for the prevention of ...... analysis of randomized trials.
@nl
type
label
Aspirin for the prevention of ...... analysis of randomized trials.
@ast
Aspirin for the prevention of ...... analysis of randomized trials.
@en
Aspirin for the prevention of ...... analysis of randomized trials.
@nl
prefLabel
Aspirin for the prevention of ...... analysis of randomized trials.
@ast
Aspirin for the prevention of ...... analysis of randomized trials.
@en
Aspirin for the prevention of ...... analysis of randomized trials.
@nl
P2093
P921
P1476
Aspirin for the prevention of ...... analysis of randomized trials.
@en
P2093
Anuradha Lala
Gizelle S Baker
Jeffrey S Berger
Mori J Krantz
William R Hiatt
P304
P356
10.1016/J.AHJ.2011.04.006
P407
P577
2011-07-01T00:00:00Z